Loading...
First Round of Abstract Submission Ends: Dec 31, 2026
Extended Early Bird Ends: Sep 28, 2026

Keynote Speakers

Prof. Claudio Bucolo
University of Catania, Italy
Title: New pharmacological insights in diabetic retinopathy
Prof. Claudio Bucolo is Full Professor of Pharmacology at the University of Catania. Prof. Claudio Bucolo held, for several years, the position of Visiting Scholar in Pharmacology at the Eye Research Institute of the Oakland University (Rochester, MI, USA).

He was the first Italian to receive the international "Dr. Roger Vogel Award for Pharmaceutical Research 2015” for the significant contribution in the field of research of new drugs for the treatment of ophthalmic diseases. In 2014 he received the "Silver Fellow Medal" of the Association for Research in Vision and Ophthalmology and in 2019 he received the "Gold Fellow Medal" with the following motivation: "In honor of outstanding service to the eye and vision community”. In 2019, the Neuroscience Center of Excellence of Louisiana State University awarded Prof Bucolo the prestigious "Chancellor's Award Guest" award with the following motivation: "For exceptional contributions to pharmacology applied to ophthalmology and outstanding academic leadership". Prof. Bucolo research mainly concern the field of ocular pharmacology and neuropharmacology. Prof. Claudio Bucolo is the author of over 240 scientific articles published in peer-reviewed journals and book chapters.

During his career he has filed 11 international patents in the field of pharmacological research. He is a reviewer of Ministry of University & Research and Agence National de la Recherche projects and is Associate Editor of scientific journals in the field of pharmacology. From 2012 to 2013 he was President of the Pharmacology Section of the Organizing Committee of the ARVO (Association for Research in Vision and Ophthalmology, Rockville, MD, USA- Association with about 12000 members) annual conference and was re-elected in 2016 as a member of the ARVO Conference Organizing Committee; from May 2018 until May 2019 he again held the role of President of the Pharmacology Section of the Organizing Committee of the ARVO annual Conference; from 2004 to 2008 he was board of trustee of the Association for Ocular Pharmacology and Therapeutics and re-elected in March 2019 again as board of trustee. Further, he organized, in the past 20 years, a series of European Frontiers Lectures delivered by outstanding European scientists and the annual IT-ARVO meeting on ocular pharmacology in addition to the series of seminars for all UniCT doctoral students entitled “Ph.D. Days”. He seats in several Editorial Boards of scientific journals such as Editorial Board Member of Journal of Ocular Pharmacology and Therapeutics; Executive Editor of Experimental Eye Research; Associate Editor di Frontiers in Pharmacology; Editorial Board Member of International Journal of Molecular Sciences Section “Molecular Pharmacology”. Furthermore, Prof. Bucolo is member of the historic Gioenia Academy established in 1824.

From 25/11/2020 to 18/09/2025, Prof. Bucolo was Deputy Rector for Education in PhD Programs and Masters.

Currently, he is the Coordinator of the PhD Program in Neuroscience.

From 05/2017 to 07/2025, Prof. Bucolo was Director of the Research Center in Ocular Pharmacology of the University of Catania (CERFO).

Currently, he is the Director of CERD (Centre for Research and in Drug Regulatory Affairs).

He also acts as liaison between the BIOMETEC Department and the School of Excellence of the University of Catania.

Bibliometric indexes: Hi = 58; citation= 10160; number of publicazions = 243.
Prof. Bassem Shaban Sadek
United Arab Emirates University, UAE
Title: Dual G9A Inhibition and Histamine H3 Receptor Antagonism in Autism Spectrum Disorder: Preclinical Evidence
Prof. Dr. Bassem Shaban Sadek is a Full Professor in the Department of Pharmacology and Therapeutics at the College of Medicine and Health Sciences, United Arab Emirates University (UAEU), Al Ain, UAE. He obtained his Ph.D. in Pharmaceutical Medicinal Chemistry and Drug Design from the Free University of Berlin, Germany, in 1999.

Professor Sadek’s research focuses on behavioral neuropharmacology, neuroscience, and preclinical drug development for neurodevelopmental, neuropsychiatric, and neurodegenerative disorders. He has extensive research experience in histamine H3 receptor pharmacology and the development of novel, multitargeted therapeutic strategies. His current research investigates the dual inhibition of G9a and antagonism of histamine H3 receptors as a potential therapeutic approach for autism spectrum disorder, supported by preclinical evidence.

With more than 130 scientific papers published and an H-index of 41, Professor Sadek has established a strong international research profile. He has received multiple research awards and secured competitive research funding for his contributions to neuropharmacology. His work aims to advance understanding of disease mechanisms and support the development of innovative therapeutic approaches.